the lack of prostate specificity and intercellular localization of its gene product make this gene a poor serum biomarker. FN1 (fibronectin 1) and VEGF (vascular endothelial growth factor) are associated with prostate cancer and encode secreted proteins; however, these genes lack prostate-specific tissue specificity (15) (16) (17) (18) . The lack of prostate tissue specificity in the expression of these 2 genes may be a major reason why they are not yet used clinically as prostate cancer serum biomarkers.
We have developed a bioinformatics protocol for screening candidate serum biomarker sets to identify high-quality markers for experimental evaluation. The in silico secreted protein pipeline provides a rapid screen for identifying biomarkers found extracellularly and is likely to be detectable by serum assays. Tissue specificity profiling compliments secreted protein prediction by identifying the originating tissue components of a biomarker's serum signal and by allowing investigators to select candidate markers with a higher probability of having distinguishable signals. We hope that the use of intelligent bioinformatics analysis before costly experimental evaluation will accelerate the selection of candidate biomarkers that can be successfully translated into novel, clinically useful, assays.
This work was supported under a grant by Invitrogen.
Representational Fragment Amplification: Exponential Amplification of Fragmented cDNA Enables Multimillion-Fold Expression Testing Gregory D. Sgarlato and Howard H. Sussman
* (Department of Pathology, Stanford University, Stanford, CA; * address correspondence to this author at: Stanford University, Lane Building, L217, Stanford, California 94305; fax 650-725-6902, email hsussman@stanford.edu) Microarray analysis, which enables the comprehensive examination of many thousands of genes in a single experiment, is a promising method for furthering understanding of disease states. Because of the large amounts of probe required, however, microarray analysis has not We analyzed 7 genes by the secretion and specificity prediction methods described above. KLK3 and ACPP (positive controls) possess the secretion and prostate specificity characteristics that we describe as key for serum biomarkers. Negative controls include ZWINT, AMACR, and HPN, which fail to encode secreted proteins, and FN1 and VEGF, which lack prostate specific tissue expression.
a Moderate refers to genes expressed in prostate and several other tissues.
been possible for small excision biopsies, fine needle aspirates, and microdissected tissue samples. Linear amplification of target cDNA with T7 RNA polymerase (1 ) is currently the most common method for the amplification of RNA for microarray analysis and has been validated (2 ) and optimized (3, 4 ) . Other linear RNA amplification strategies have been developed (5, 6 ) , but these do not generate sufficient amounts of probe for microarray analysis. DNA fragments have been used for enriching populations (7 ), cloning differences (8 ) , and subtractive screening (9 ) . Representational fragment amplification (RFA) is a method that we have developed for global amplification of cDNA as universally primed fragments. The product of RFA is double-stranded DNA, which can be directly labeled for microarray analysis, screened for genetic variation with traditional probes, analyzed with PCR-based protocols, or stored for future analysis.
To perform RNA isolation, we processed paired nondiseased and diseased cervical biopsy samples from patients diagnosed with squamous cell carcinoma of the cervix as previously described (10 ) . The specimens were anonymized by ILS Bio or Genomics Collaborative and collected with patient consent in compliance with the company Institutional Review Boards and with the Code of Federal Regulations (CFR) 45CFR46.101B. Briefly, tissue samples frozen with liquid nitrogen were ground to a fine powder, transferred to 6-mol/L guanidine-HCL at room temperature, and homogenized by multiple passes through a syringe equipped with an 18-gauge needle. We isolated RNA with a Qiagen RNeasy Midi Kit.
For RFA cDNA synthesis, we used 5 g of RNA from nondiseased and diseased tissues as templates in the Roche cDNA Synthesis System, according to manufacturer's instructions, substituting 2 mmol/L PolyT18_DpnII/ NlaIII-V (5Ј-GAG AGT GAG TGA TCA TGT TTT TTT TTT TTT TTT TTV-3Ј) as the primer.
For in vitro transcription synthesis, we used 10 g of total RNA and followed the protocols for the Affymetrix in vitro transcription (IVT) Kit. For microscale cDNA synthesis, we used 10 ng total RNA from Human Universal Reference RNA (UHRR) (Stratagene, Inc.) and Human Breast Carcinoma T-47 Cell Line Total RNA (Ambion, Inc.). We established a template for cDNA synthesis through dilution in 10 mmol/L Tris pH 8.0 containing 30 mg/L polyinosinic acid carrier (11 ) . One of the volumes of the Roche reagent set were used. For microscale cDNA synthesis, we added 20 g of T4gp32 (12 ) immediately before the addition of reverse transcriptase. Microscale cDNA samples were heat killed and were not treated with RNase or proteinase K.
For RFA amplicon synthesis, cDNA fractions (1/6 to 1/12) were digested with DpnII or NlaIII for 90 min at 37°C, heat killed at 65°C for 90 min, and ligated to 5 g of the appropriate preassembled linker (3 to 16 hrs). The DpnII linker was assembled with R-BGL-24, sequence 5Ј-AGC ACT CTC CAG CCT CTC ACC GCA-3Ј, and R-BGL-12, sequence 5Ј-GAT CTG CGG TGA-3Ј) (9 ) and the NlaIII linker is assembled with: R-BGL-28_NlaIII, sequence 5Ј-AGC ACT CTC CAG CCT CTC ACC GCA CAT G-3Ј and R-Bgl-08_NlaIII, sequence 5Ј-TGC GTGA-3Ј). Linker-ligated cDNA dilutions were the templates for amplifications. Amplification was performed on 4 to 6 identical 100-L tubes containing diluted template, 100 pmol/L R-BGL-24 primer, and (final concentration) 66 mmol/L Tris-HCl pH 8.8 at 25°C, 16 mmol/L (NH4) 2 SO 4 , 4 mmol/L MgCl 2 , and 0.2 mmol/L each dNTP. The amplification tubes were incubated at 72°C for 3 min before the addition of 5 units of Taq polymerase. The 72°C incubation continued for 10 min before 20 -28 cycles at 95°C for 15 s and 72°C for 3 min. The DpnII and NlaIII amplicons were pooled, phenol/chloroform extracted, and isopropanol precipitated and resuspended in 100 L TE Ϫ1 (1 mM Tris pH 8.0, 0.1 mmol/L EDTA). The RFA amplicons were diluted in water and quantitated by A 260 and checked for purity by A 260 /A 280 ratio.
For microscale RFA amplicon synthesis, linker ligations contained 1 g of linker in a 25 L volume. We calculated the target for 25 cycles of RFA to be 15.8 pg of mRNA. The yield of double-stranded probe was 25 g: net 1.5 millionfold.
Our improved precipitation protocols were performed with equal-volume isopropanol precipitations with 0.3 mol/L sodium acetate, pH 5.3, incubated at Ϫ80°C for at least 2 h. Ethanol washes were 85% ethanol.
The primer designs and protocols for real-time quantitative reverse transcriptase (RT)-PCR were taken from previously published experiments (10 ) , and the amplified segments were free of DpnII and NlaIII restriction sites (CCNB1 primers; 3-2 PRIME-195F: TGG TCT GGG TCG GCC TC, 3-2 PRIME-263R: TCG ACA TCA ACC TCT CCA ATC TT, 3-2 213FT: ACC TTT GCA CTT CCT TCG GAG AGC ATC). We used specific fluorescein/tetramethylrhodamine probes, and cycling was 95°C, 15 s and 65°C, 3 min for 40 cycles. For each independent gene assay, we used actin diseased/nondiseased (D/N) ratios from cDNA to normalize the gene D/N ratios of the amplicon. The mean normalization factor was 30%.
For random primer biotinylation, we biotinylated RFA amplicons in 4 -6 independent, replicate BioPrime ® DNAlabeling reactions (0.5 g target) (13 ) , following the manufacture's protocols (Invitrogen, Inc), and obtained a mean 10-fold yield.
For all microarray analysis experiments, we followed the manufacturer's hybridization and processing protocols for the HU133 plus 2.0 chips. We used Affymetrix Microarray Analysis Suite (GCOS v1.0) and ArrayAssist (3.3) (Stratagene, Inc) to import Affymetrix CEL files and to generate intensity values based on the robust multiarray average method (14 ) . The relationships between the different platforms were assessed by Pearson correlation coefficients (15, 16 ) .
The RFA method uses 2 enzymes to fragment the cDNA in a known, reproducible manner (Fig. 1A) . To give every cDNA fragment a common priming site at both ends, the cDNA fragments are ligated to compatible adaptors containing the R-BGL-24 universal primer sequence. Amplification of these smaller cDNA fragments proceeds exponentially and can be used to generate expression Clinical Chemistry 52, No. 11, 2006 signatures. We used the synthesis rate definition for 5 units of Taq DNA polymerase to establish the goal of 5 g of DNA per 100 L (40 g/8 tubes).
Complete real-time quantitative RT-PCR analysis of 6 gene transcripts for 3 paired cervical biopsy samples (10 ) are presented in Table 1 . These quantitative results demonstrate that RFA is a robust methodology that can produce accurate DNA signatures from limited amounts of starting material. For each patient, we compared the gene-fragment concentrations from the DpnII and NlaIII amplicons with gene concentrations in the original cDNA to determine whether these amplicons maintained the relative D/N expression ratios seen in the cDNA. For all patients the RFA amplification was Ͼ100 000-fold, and the mean CV for the all analyses was 11.8%.
Yields of RFA amplicon were determined by harvesting identical tubes at different cycles of amplification. The net yield data from 5 tubes of pooled amplification are plotted in Fig. 1B . For statistical comparison, we established replicate hybridization experiments, generating 6-tube and 24-tube pools from 24 cycles of amplification from identical target. The R 2 values were 0.9971 for the duplicate hybridizations to Affymetrix U133A plus chips and 0.9934 for the 6-tube pool vs the 24-tube pool. Scatterplot representation of values Ͼ100 for the 6-tube vs 24-tube pools are shown in Fig. 1C . Agilent 2100 Bioanalyzer analysis showed that most of the products of the RFA protocols were 100 to 700 bases in length.
To validate the independent repeatability of small-scale amplifications, we established microscale cDNA synthesis protocols (10 ng total RNA) that used independent IVT (T7) results to compare and contrast the independent 15-million-fold RFA results. We used UHRR as the control sample for the Breast Carcinoma Cell line (T-47) microarray experiments designed to compare the RFA and T7 platforms (17 ) . Amplification was 200-fold for the duplicate pair of IVT samples, with a mean duplicate array correlation of 0.9822, and 15-million-fold for the There is an increasing need for high-sensitivity immunoassays that can be used in point-of-care patient testing of complex media. For example, analytes such as the natriuretic peptides and recently discovered sepsis markers are found in blood in very low picomolar concentrations (1, 2 ) . Although advances have been made in the use of fluorescent, chemiluminescent, and other labels to measure markers at lower detection limits, background interference from biological samples and detection instrumentation remains problematic. Optical biosensors offer the promise of label-free real-time measurements, but their application to quantification of analytes in complex media is impaired by higher detection limits and is susceptible to changes in refractive indices or nonspecific surface binding. Moreover, the costliness of these devices has largely prohibited bedside implementation. In this report, we detail the use of a novel diffractive optics technology (dot™) that takes advantage of the inherent properties of diffractive optics to deliver a cost-effective, portable, robust, optical biosensor that detects analytes at picomolar concentrations in complex media.
In the dotLab TM System, coherent light striking a nonrandom pattern of capture molecules on the dotLab Sensor creates constructive and destructive interferences that produce a well-defined diffraction image. As molecules bind to the capture molecules, the height of the diffraction pattern is increased, which in turn increases the diffraction efficiency and the diffractive order intensity. A photodiode monitors the intensity of the diffractive order, which is correlated to analyte concentrations. Because diffraction is inherently self-referencing, the transduction of binding events is dependent on the initial pattern, and an increase in diffractive order intensity will occur only if molecules bind exclusively to the patterned capture reagents. Therefore, nonspecific binding to both the patterned and nonpatterned regions will not affect the signal, a characteristic that offers an important advantage over other optical biosensor systems in which any surfacebinding event will cause an increase in signal.
Previous diffraction-based immunosensors have used silicon wafer chips that were in contact with analytecontaining solutions and required washing and drying before analysis by a simple reader (3 ). The dotLab system uses a plastic consumable, the dotLab Sensor, with an integrated prism situated below the flow channel so that the light source interrogates the diffraction grating without passing through the bulk solution. Previous studies suggest that this total internal reflection scheme allows for 95% of the laser intensity to be measured, whereas in a nontotal internal reflection set-up only 5% is measured (4 ) . Moreover, with this configuration, our system monitors biomolecule binding in real time and in complex media.
We tested the beta prototype of the dotLab instrument, which incorporates the core dot technology in an integrated package intended for in-house and controlled external development work. The instrument includes precision fluidic control of reagents, buffers, and samples-a proprietary integrated optical assembly designed to function with the dotLab Sensor; and software for acquisition, control, and user-interface. A movable stage allows monitoring and potential patterning with different capture reagents for 8 discrete diffraction spots. In addition, each individual spot can be cross-patterned to perform intraspot multiplexing and assays, as we have previously demonstrated (5, 6 ) .
We used a single-spot and a streptavidin-patterned sensor with reagents for the detection of N-terminal probrain natriuretic peptide (NT-proBNP) in various matrices at reference concentrations, as summarized in Table  1 . For direct detection of recombinant NT-proBNP, we used a biotinylated monoclonal antibody directed against NT-proBNP immobilized on a streptavidin-patterned dotLab Sensor (Fig. 1A) . The binding event can be observed in real time in the trace. The binding of recombinant NT-proBNP is also detected, but at a lower intensity. The recombinant protein has a low relative molecular mass (M r ) of ϳ8000, which generates very little signal on its own. At lower concentrations, we used a different format to enhance the diffraction signal. For example, to detect NT-proBNP at nanomolar concentrations, we used a combination of capture and detector antibodies (Fig. 1B) , with which the binding of the biotinylated mouse capture antibody was readily detected, whereas the introduction of the recombinant protein did not produce a detectable signal increase.
We carried out rinse steps with pulses of phosphate buffered saline (PBS) (137 mmol/L NaCl; 2.7 mmol/L KCl; 10 mmol/L Na 2 HPO 4 /KH 2 PO 4 , pH 7.4; OmniPur) and PBS-Tween (10 mmol/L phosphate buffer, pH 7.4; 140 mmol/L NaCl; 3 mmol/L KCl; 0.025% (w/v) Tween-20; Calbiochem). When we introduced a polyclonal goat antibody directed against NT-proBNP, the diffraction signal increased. For internal calibration purposes and to
